onc Videos

Videos

Conference Coverage

Utilizing and Selecting Optimal JAK Inhibitor Therapies for Patients With Myelofibrosis

09/12/2024

At the 2024 SOHO meeting, John Mascarenhas, MD, shares highlights from a discussion on the utilization and selection of optimal JAK inhibitor therapies for the treatment of patients with myelofibrosis.

At the 2024 SOHO meeting, John...

09/12/2024

Oncology

Conference Coverage

New and Upcoming Combination and Non-JAK Inhibitor Treatments for Patients With Myelofibrosis

09/12/2024

John Mascarenhas , MD;

At the 2024 SOHO meeting, John Mascarenhas, MD reviewed the latest data in myelofibrosis treatment options, including upcoming novel combination and non-JAK inhibitor therapies.

At the 2024 SOHO meeting, John...

09/12/2024

Oncology

Conference Coverage

The “ABCs” of Immunotherapy for Patients With Acute Myeloid Leukemia

09/06/2024

At the 2024 SOHO meeting, Marion Subklewe, MD, discusses the current landscape and future development of immune and cellular therapies for patients with acute myeloid leukemia.

At the 2024 SOHO meeting, Marion...

09/06/2024

Oncology

Conference Coverage

Challenges of Treating Secondary Acute Myeloid Leukemia With Standard Therapies

09/05/2024

Pinkal Desai, MD discusses the challenges of existing treatment options for patients with secondary acute myeloid leukemia and the need for further development of therapies for this disease subset.

Pinkal Desai, MD discusses the...

09/05/2024

Oncology

Alessandro Santin, MD, Yale Cancer Center

Videos

Efficacy and Safety of Sacituzumab Govetican for Patients With Advanced Endometrial Cancer

09/05/2024

Alessandro Santin, MD, shares insights from the endometrial cancer cohort of the TROPiCS-03 trial, which evaluated sacituzumab govetican among patients with advanced endometrial cancer who have been heavily pretreated.

Alessandro Santin, MD, shares...

09/05/2024

Oncology

Conference Coverage

Developments in Utilizing Interferons for the Treatment of Myeloproliferative Neoplasms

09/04/2024

Abdulraheem Yacoub , MD;

Abdulraheem Yacoub, MD, shares expert insight into the use of interferons for the treatment of patients with myelofibrosis, essential thrombocythemia, and polycythemia vera.

Abdulraheem Yacoub, MD, shares...

09/04/2024

Oncology

Conference Coverage

Exploring Developments and Challenges of Immunological Approaches in AML Treatment

09/04/2024

Eduardo Rego , MD, PhD;

At the 2024 Society of Hematologic Oncology meeting, Eduardo Rego, MD, shares his interest in reviewing data on novel research in acute myeloid leukemia treatment development, specifically the incorporation of immunological approaches.

At the 2024 Society of...

09/04/2024

Oncology

Conference Coverage

Analyzing Data on the Improvement of International Outcomes of Acute Myeloid Leukemia Therapy

09/04/2024

Eduardo Rego, MD, shares expert insight into International Consortium on Acute Leukemia research on improving the outcomes of therapy for patients with AML treated in Latin America compared to the outcomes of those treated in the US and...

Eduardo Rego, MD, shares expert...

09/04/2024

Oncology

Videos

Potential for Measurable Residual Disease as an End Point in Chronic Lymphocytic Leukemia Research

09/03/2024

Talal Hilal, MD, discusses an analysis on whether measurable residual disease can serve as a valuable end point in chronic lymphocytic leukemia clinical trials.

Talal Hilal, MD, discusses an...

09/03/2024

Oncology

Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute

Videos

Inavolisib Plus Palbociclib and Fulvestrant for Patients With Relapsed PIK3CA-Mutated Advanced Breast Cancer

09/03/2024

Demetria J. Smith-Graziani , MD, MPH;

Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...

Demetria Smith-Graziani, MD,...

09/03/2024

Oncology

Recent News

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology

News

Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer

11/05/2024

Stephanie Holland ;

Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.

Results from the phase 2 SWOG...

11/05/2024

Oncology